Lupus
45
12
13
17
Key Insights
Highlights
Success Rate
81% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.9%
4 terminated out of 45 trials
81.0%
-5.5% vs benchmark
2%
1 trials in Phase 3/4
24%
4 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 17 completed trials
Clinical Trials (45)
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Patient-Centered Assessment of Symptoms and Outcomes
A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
Cardiac Imaging in Systemic Disorders: the ORACLES Registry
The Burden of Lupus in Canada From a Patient Perspective: A Canadian Real-World PROxy Study
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
Helping Lupus Patients Manage Fibromyalgia Symptoms Through Emotional Awareness and Expression Therapy (EAET)
Complete Cognitive Intervention for cSLE
Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study
Safety and Efficacy of ONT01 in Lupus
Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)
UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients
Direct to Patient Minimal Risk Biospecimen and Data Collection Research
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress
S100A8 in Serum and Urine as a New Biomarker in Lupus Nephritis
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Lupus